Eli Lilly (LLY) Return on Equity (2009 - 2026)

Eli Lilly (LLY) has reported Return on Equity for 17 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, up 12.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 12.0% YoY), and the FY2025 annual result was 0.02%, up 9.0% from the prior year.
• Return on Equity was 0.01% for Q1 2026 at Eli Lilly, up from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.02% in Q3 2025 and troughed at 0.13% in Q4 2024.
• Average Return on Equity over 5 years is 0.04%, with a median of 0.03% recorded in 2022.
• Year-over-year, Return on Equity dropped 10 bps in 2024 and advanced 14 bps in 2025.
• Over 5 years, Return on Equity stood at 0.03% in 2022, then decreased by 15 bps to 0.03% in 2023, then sank by 277 bps to 0.13% in 2024, then soared by 106 bps to 0.01% in 2025, then gained by 7 bps to 0.01% in 2026.
• Per Business Quant data, the three most recent Return on Equity figures were 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.02% in Q3 2025.